Phase II study of tirapazamine, cisplatin, and etoposide and concurrent thoracic radiotherapy for limited-stage small-cell lung cancer: SWOG 0222.

Publication Type:

Journal Article


Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Volume 27, Issue 18, p.3014-9 (2009)


2009, Adult, Aged, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Cisplatin, Combined Modality Therapy, Esophagitis, Etoposide, Female, Humans, Lung Neoplasms, Male, Middle Aged, NEUTROPENIA, Public Health Sciences Division, Small Cell Lung Carcinoma, Survival Rate, Triazines


A SWOG pilot study (S0004) showed that tirapazamine (TPZ) when combined with concurrent chemoradiotherapy yielded a promising median survival of 22 months in limited-stage small-cell lung cancer (LSCLC). We report results of the phase II study designed to confirm this result.